VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome is a rare clinical entity first described in 2020 and characterized by acquired mutations typically involving p. Met41 in the ubiquitin‐like modifier activating enzyme 1 (UBA1) gene [1]. This evidence concerns the gene UBA1 and VEXAS syndrome.